Dual Antibody

Dual Antibody represents therapeutic constructs simultaneously targeting two distinct antigens or epitopes, enabling mechanisms of action impossible with conventional monospecific antibodies through coordinated engagement of multiple molecular targets. These engineered molecules encompass diverse formats including bispecific antibodies binding different antigens on separate arms, dual-variable-domain immunoglobulins incorporating additional binding sites, and tandem single-chain variable fragments linking multiple specificities. Dual antibody approaches address complex diseases requiring simultaneous pathway modulation, redirect immune effector cells to diseased tissues, or achieve synergistic effects through coordinated target engagement.

The biopharmaceutical industry has invested extensively in dual antibody platforms, with multiple approved products validating therapeutic potential particularly in oncology and immunology. T-cell engagers represent prominent dual antibody applications, simultaneously binding tumour antigens and CD3 on T cells, forming immune synapses triggering potent tumour cell killing. Development challenges include ensuring proper chain pairing in production preventing unwanted antibody combinations, achieving balanced affinities for both targets, and managing increased complexity in manufacturing and characterisation. Analytical characterisation requires demonstrating correct assembly, quantifying undesired byproducts, and confirming dual binding activity. Clinical development addresses unique pharmacology from simultaneous target engagement and potential for unexpected toxicities. As understanding of disease biology reveals interconnected pathways and single-target approaches show limitations, dual antibody therapeutics continue proliferating with novel target combinations and expanded applications.